Spotlight
Clinical Role
Clinical
Supplement Spotlight
CME/CE
Subscribe
Targeted Therapy Treatment Innovations in AML : Episode 8
5-Year Follow-Up Data For CPX-351 in AML
Alexandra S. Wolff, PharmD, BCOP, explores the 5-year follow-up data from the phase 3 trial of CPX-351 in AML.
EP: 1.Role of First Generation FLT3 Inhibitors in AML
EP: 2.Role of Second Generation FLT3 Inhibitors in AML
EP: 3.Part 1: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML
EP: 4.Part 2: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML
EP: 5.Role of Venetoclax in Treatment of AML
EP: 6.Part 1: Practical Considerations For Venetoclax in AML
EP: 7.Part 2: Practical Considerations For Venetoclax in AML
Now Viewing
EP: 8.5-Year Follow-Up Data For CPX-351 in AML
EP: 9.CPX-351 in Clinical Practice For AML
Recent Videos
Related Content
